Source comparison
Thymosin Alpha-1 Research Review: Clinical Comparison
Chronic Hepatitis B/C 1.6mg SC twice weekly, 12–24 weeks IL-2 receptor upregulation, IFN-α production 18–24% improvement in sustained virological response vs antiviral alone (Lancet Infect Dis 2018) Injection-site reactions <10%, systemic AE <5% Strong adjunct
This comparison does not assign a generated winner or score.
- Chronic Hepatitis B/C
- 1.6mg SC twice weekly, 12–24 weeks
- IL-2 receptor upregulation, IFN-α production
- 18–24% improvement in sustained virological response vs antiviral alone (Lancet Infect Dis 2018)
- Injection-site reactions <10%, systemic AE <5%
- Strong adjunct evidence; most benefit in low baseline T-cell patients
- Cancer Immunotherapy Adjunct
- 1.6mg SC twice weekly during/after chemo
- Dendritic cell maturation, T-cell restoration
- 19% recurrence reduction in stage II–III melanoma (Lancet Oncol)
- Well-tolerated; no autoimmune signals documented
- Useful in immune-suppressed oncology patients; not a standalone therapy
- Vaccine Response (Elderly)
- 1.6mg SC twice weekly × 4 weeks with vaccine
- Enhanced antigen presentation via dendritic cells
- Seroconversion 78% vs 52% placebo; 2.1× antibody titers (Vaccine)
- Comparable to placebo
- Compelling data in immunosenescent populations; dose-dependent effect
- Severe COVID-19 (Adjunct)
- 1.6mg SC daily or BID, 7–14 days
- IFN pathway activation, lymphopenia correction
- 28-day mortality 14.2% vs 26.3% placebo in Chinese cohort
- No safety signals in acute use
- Mechanistically sound; awaits replication in diverse populations